A bisaryl (thio)morpholine derivative of the formula wherein R1 is an aryl substituent selected from phenyl, pyridyl, pyrimidinyl, biphenyl and naphthyl, each optionally substituted with one or more substituents independently selected from halogen, alkyl optionally substituted with one or more fluoro atoms, alkoxy optionally substituted with one or more fluoro atoms, amino, di alkylamino, -SO 2 - alkyl, -CO- alkyl, -CO-O- alkyl and -NH-CO- alkyl, or substituted with phenoxy, benzyl, benzyloxy, phenylethyl or morpholinyl, each optionally substituted with alkyl, and bicyclic group, bicyclic heterocycle, each optionally substituted with alkyl optionally substituted with one or more fluoro atoms or oxo; A is selected from -CO-, -NH-, -O-, -S-, -SO- or -SO 2 -; ring structure B optionally contains one nitrogen atom; R2 is H, alkyl optionally substituted with one or more fluoro atoms, alkoxy optionally substituted with one or more fluoro atoms, or halogen; and R3 is alkylene-R6 wherein the alkylene group may be substituted with (CH 2) 2 to form a cyclopropyl moiety or with one or more halogen atoms, or R3 is cycloalkylene-R5 or -CO-CH 2 -R6, wherein R6 is -OH, - PO 3 H 2, -OPO 3 H 2, -COOH, -COO( 1 -4C)alkyl or tetrazol-5-yl; R4 is H or alkyl; R5 is one or more substituents independently selected from H, alkyl or oxo; W is -O-, -S-, -SO- or -SO 2 -; or a pharmaceutically acceptable salt, a solvate or hydrate thereof, with the proviso that the derivative of formula is not 2-[4-(4-chlorophenoxy)-2-chloro-phenyl]-4-morpholineethanol. R1 is an aryl substituent selected from phenyl, pyridyl, pyrimidinyl, biphenyl and naphthyl, each optionally substituted with one or more substituents independently selected from halogen, alkyl optionally substituted with one or more fluoro atoms, alkoxy optionally substituted with one or more fluoro atoms, amino, di alkylamino, -SO 2 - alkyl, -CO- alkyl, -CO-O- alkyl and -NH-CO- alkyl, or substituted with phenoxy, benzyl, benzyloxy, phenylethyl or morpholinyl, each optionally substituted with alkyl, and bicyclic group, bicyclic heterocycle, each optionally substituted with alkyl optionally substituted with one or more fluoro atoms or oxo; phenyl, pyridyl, pyrimidinyl, biphenyl and naphthyl, each optionally substituted with one or more substituents independently selected from halogen, alkyl optionally substituted with one or more fluoro atoms, alkoxy optionally substituted with one or more fluoro atoms, amino, di alkylamino, -SO 2 - alkyl, -CO- alkyl, -CO-O- alkyl and -NH-CO- alkyl, or substituted with phenoxy, benzyl, benzyloxy, phenylethyl or morpholinyl, each optionally substituted with alkyl, and bicyclic group, bicyclic heterocycle, each optionally substituted with alkyl optionally substituted with one or more fluoro atoms or oxo; A is selected from -CO-, -NH-, -O-, -S-, -SO- or -SO 2 -; ring structure B optionally contains one nitrogen atom; R2 is H, alkyl optionally substituted with one or more fluoro atoms, alkoxy optionally substituted with one or more fluoro atoms, or halogen; and R3 is alkylene-R6 wherein the alkylene group may be substituted with (CH 2) 2 to form a cyclopropyl moiety or with one or more halogen atoms, or R3 is cycloalkylene-R5 or -CO-CH 2 -R6, wherein R6 is -OH, - PO 3 H 2, -OPO 3 H 2, -COOH, -COO( 1 -4C)alkyl or tetrazol-5-yl; R4 is H or alkyl; R5 is one or more substituents independently selected from H, alkyl or oxo; W is -O-, -S-, -SO- or -SO 2 -; or a pharmaceutically acceptable salt, a solvate or hydrate thereof, with the proviso that the derivative of formula is not 2-[4-(4-chlorophenoxy)-2-chloro-phenyl]-4-morpholineethanol.